SLC25A19 deficiency and bilateral striatal necrosis with polyneuropathy: a new case and review of the literature

Francesco Porta; Barbara Siri; Nicoletta Chiesa; Federica Ricci; Lulash Nika; Paola Sciortino; Marco Spada

doi:10.1515/jpem-2020-0139

Artikel

SLC25A19 deficiency and bilateral striatal necrosis with polyneuropathy: a new case and review of the literature

Francesco Porta , Barbara Siri , Nicoletta Chiesa , Federica Ricci , Lulash Nika , Paola Sciortino und Marco Spada

Veröffentlicht/Copyright: 19. November 2020

Veröffentlicht von

Veröffentlichen auch Sie bei De Gruyter Brill

Manuskript einreichen Informationen für Autor*innen Erkunden Sie dieses Fachgebiet

Aus der Zeitschrift Journal of Pediatric Endocrinology and Metabolism Band 34 Heft 2

Abstract

Objectives

Biallelic mutations in the SLC25A19 gene impair the function of the thiamine mitochondrial carrier, leading to two distinct clinical phenotypes. Homozygosity for the c.530G > C mutation is invariably associated to Amish lethal microcephaly. The second phenotype, reported only in 8 patients homozygous for different non-Amish mutations (c.373G > A, c.580T > C, c.910G > A, c.869T > A, c.576G > C), is characterized by bilateral striatal necrosis and peripheral polyneuropathy. We report a new patient with the non-Amish SLC25A19 phenotype showing compound heterozygosity for the new variant c.673G > A and the known mutation c.373G > A.

Case presentation

The natural history of non-Amish SLC25A19 deficiency is characterized by acute episodes of fever-induced encephalopathy accompanied by isolated lactic acidosis and Leigh-like features at magnetic resonance imaging (MRI). Acute episodes are prevented by high-dose thiamine treatment (600 mg/day). As shown in the new case, both mild clinical signs and basal ganglia involvement can precede the acute encephalopathic onset of the disease, potentially allowing treatment anticipation and prevention of acute brain damage. Peripheral axonal neuropathy, observed in 7 out of 9 patients, is not improved by thiamine therapy. In two early treated patients, however, peripheral neuropathy did not occur even on long-term follow-up, suggesting a potential preventive role of treatment anticipation also at the peripheral level.

Conclusions

Non-Amish SLC25A19 deficiency is an extra-rare cause of Leigh syndrome responsive to thiamine treatment. Ex adiuvantibus thiamine treatment is mandatory in any patient with Leigh-like features.

Keywords: leigh syndrome; mitochondrial diseases; SLC25A19; thiamine

Corresponding author: Dr. Francesco Porta, MD, PhD, Department of Pediatrics, University of Torino, Piazza Polonia 94, 10126Torino, Italy, Phone: +39 011 6637777, Fax: +39 011 3135382, E-mail: francesco.porta@unito.it

Research funding: None declared.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Competing interests: None declared.

References

1. Manzetti, S, Zhang, J, van der Spoel, D. Thiamin function, metabolism, uptake, and transport. Biochemistry 2014;53:821–35. https://doi.org/10.1016/10.1021/bi401618y.Suche in Google Scholar

2. Mkrtchyan, G, Aleshin, V, Parkhomenko, Y, Kaehne, T, Di Salvo, ML, Parroni, A, et al.. Molecular mechanisms of the non-coenzyme action of thiamin in brain: biochemical, structural and pathway analysis. Sci Rep 2015;5:12583. https://doi.org/10.1016/10.1038/srep12583.Suche in Google Scholar

3. Marcé-Grau, A, Martí-Sánchez, L, Baide-Mairena, H, Ortigoza-Escobar, JD, Pérez-Dueñas, B. Genetic defects of thiamine transport and metabolism: a review of clinical phenotypes, genetics, and functional studies. J Inherit Metab Dis 2019;42:581–97. https://doi.org/10.1002/jimd.12125.Suche in Google Scholar PubMed

4. Siu, VM, Ratko, S, Prasad, AN, Prasad, C, Rupar, CA. Amish microcephaly: long-term survival and biochemical characterization. Am J Med Genet 2010;7:1747–51. https://doi.org/10.1016/10.1002/ajmg.a.33373.Suche in Google Scholar

5. Spiegel, R, Shaag, A, Edvardson, S, Mandel, H, Stepensky, P, Shalev, SA, et al.. SLC25A19 mutation as a cause of neuropathy and bilateral striatal necrosis. Ann Neurol 2009;66:419–24. https://doi.org/10.1016/10.1002/ana.21752.Suche in Google Scholar

6. Ortigoza-Escobar, JD, Alfadhel, M, Molero-Luis, M, Darin, N, Spiegel, R, de Coo, IF, et al.. Thiamine deficiency in childhood with attention to genetic causes: survival and outcome predictors. Ann Neurol 2017;3:317–30. https://doi.org/10.1016/10.1002/ana.24998.Suche in Google Scholar

7. Gowda, VK, Srinivasan, VM, Jehta, K, Bhat, MD. Bilateral striatal necrosis with polyneuropathy with a novel SLC25A19 (mitochondrial thiamine pyrophosphate carrier OMIMI*606521) mutation: treatable thiamine metabolic disorder-A report of two Indian cases. Neuropediatrics 2019;50:313–7. https://doi.org/10.1016/10.1055/s-0039-1693148.Suche in Google Scholar

8. Bottega, R, Perrone, MD, Vecchiato, K, Taddio, A, Sabui, S, Pecile, V, et al.. Functional analysis of the third identified SLC25A19 mutation causative for the thiamine metabolism dysfunction syndrome 4. J Hum Genet 2019;64:1075–81. https://doi.org/10.1016/10.1038/s10038-019-0666-5.Suche in Google Scholar

9. Rahman, J, Noronha, A, Thiele, I, Rahman, S. Leigh map: a novel computational diagnostic Resource for mitochondrial disease. Ann Neurol 2017;81:9–16. https://doi.org/10.1016/10.1002/ana.24835.Suche in Google Scholar

10. Mir, A, Alhazmi, R, Albaradie, R. Biotin-thiamine-responsive basal ganglia disease-A treatable metabolic disorder. Pediatr Neurol 2018;87:80–1. https://doi.org/10.1016/10.1016/j.pediatrneurol.2018.06.006.Suche in Google Scholar

Received: 2020-03-26

Accepted: 2020-10-04

Published Online: 2020-11-19

Published in Print: 2021-02-23

Sie haben derzeit keinen Zugang zu diesem Inhalt.

Artikel in diesem Heft

https://doi.org/10.1515/jpem-2020-0139

Schlagwörter für diesen Artikel

leigh syndrome; mitochondrial diseases; SLC25A19; thiamine